p.79 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e192 37 Li Y, Staessen JA, Lu L, et al. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. Hypertension. 2007;50:333–339. 38. Gumz ML, Shimbo D, Abdalla M, et al. Toward precision medicine: circa dian rhythm of blood pressure and chronotherapy for hypertension - 2021 NHLBI workshop report. Hypertension. 2023;80:503–522. 39. Stergiou G, Brunstrom M, MacDonald T, et al. Bedtime dosing of antihy pertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40:1847–1858. 40. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a re port of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324. 3.2.3 Secondary Forms of Hypertension 1 Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300. 2. Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75:1913–1922. 3. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized preva lence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20. 4. Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med. 2017;167:630–641. 5. Jinchai J, Khamsai S, Chattakul P, et al. How common is obstructive sleep apnea in young hypertensive patients? Intern Emerg Med. 2020;15:1005– 1010. 6. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811–817. 7. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breath ing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283:1829–1836. 8. Hundemer GL, Agharazii M, Madore F, et al. Subclinical primary aldosteron ism and cardiovascular health: a population-based cohort study. Circulation. 2024;149:124–134. 9. Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifesta tions of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–1820. 10. Bhalla V, Textor SC, Beckman JA, et al. Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hyper tension. 2022;79:e128-e143. 11. Vitarello JA, Fitzgerald CJ, Cluett JL, et al. Prevalence of medications that may raise blood pressure among adults with hypertension in the United States. JAMA Intern Med. 2022;182:90–93. 12. MacIntyre IM, Turtle EJ, Farrah TE, et al. Regular acetaminophen use and blood pressure in people with hypertension: the PATH-BP trial. Circulation. 2022;145:416–423. 13. Patel KA, Bhatt MH, Hirani RV, et al. Assessment of potential drug-drug in teractions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon. 2022;8:e11278. 14. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a re port of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324. 15. Pivetta B, Chen L, Nagappa M, et al. Use and performance of the STOP- Bang questionnaire for obstructive sleep apnea screening across geo graphic regions: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e211009. 16. Bernhardt L, Brady EM, Freeman SC, et al. Diagnostic accuracy of screening questionnaires for obstructive sleep apnoea in adults in different clinical co horts: a systematic review and meta-analysis. Sleep Breath. 2022;26:1053– 1078. 17. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassess ing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268–288.e261. 18 Fu EL, Carrero JJ, Sang Y, et al. Association of low glomerular filtration rate with adverse outcomes at older age in a large population with routinely measured cystatin C. Ann Intern Med 2024;177:269–279. 19. Funder JW, Carey RM, Mantero F, et al. The management of primary aldo steronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889–1916. 20. Young WF Jr, Calhoun DA, Lenders JWM, et al. Screening for endocrine hypertension: an Endocrine Society scientific statement. Endocrine Rev. 2017;38:103–122. 21. Leung AA, Pasieka JL, Hyrcza MD, et al. Epidemiology of pheochromocy toma and paraganglioma: population-based cohort study. Eur J Endocrinol. 2021;184:19–28. 22. Ebbehoj A, Stochholm K, Jacobsen SF, et al. Incidence and clinical presen tation of pheochromocytoma and sympathetic paraganglioma: a populationbased study. J Clin Endocrinol Metab. 2021;106:e2251-e2261. 23. Isselbacher EM, Preventza O, Black JH 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a re port of the American Heart Association/American College of Cardi ology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146:e334–e482. 24. Fallo F, Di Dalmazi G, Beuschlein F, et al. Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the Euro pean Society of Hypertension. J Hypertens. 2022;40:2085–2101. 25. Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acro megaly management guidelines. Pituitary. 2021;24:1–13. 26. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. 27. Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduction in alco hol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108-e120. 28. Teramoto M, Yamagishi K, Muraki I, et al. Coffee and green tea consumption and cardiovascular disease mortality among people with and without hyper tension. J Am Heart Assoc 2023;12:e026477. 29. Penninkilampi R, Eslick EM, Eslick GD. The association between consistent licorice ingestion, hypertension and hypokalaemia: a systematic review and meta-analysis. J Hum Hypertens. 2017;31:699–707. 30. Vongpatanasin W, Kario K, Atlas SA, et al. Central sympatholytic drugs. J Clin Hypertens (Greenwich). 2011;13:658–661. 31. Luther JM, Dominiczak AF, Jennings GLR, et al. Paroxysmal hypertension associated with presyncope. Hypertension. 2019;74:718–725. 32. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disor der in children and adolescents. Pediatrics. 2019;144:. 33. Parks KA, Parks CG, Yost JP, et al. Acute blood pressure changes associ ated with antipsychotic administration to psychiatric inpatients. Prim Care Companion CNS Disord. 2018;20:18m02299. 34. Li XQ, Tang XR, Li LL. Antipsychotics cardiotoxicity: what's known and what's next. World J Psychiatry. 2021;11:736–753. 35. Cameron NA, Blyler CA, Bello NA. Oral contraceptive pills and hyperten sion: a review of current evidence and recommendations. Hypertension. 2023;80:924–935. 36. Aggarwal R, Heller G, Hillman DW, et al. PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk bio chemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol. 2024;42:1114–1123. 3.2.3.1 Primary Aldosteronism 1 Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to- plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31:619–632, xi. 2. Maiolino G, Rossitto G, Bisogni V, et al. Quantitative value of aldosteronerenin ratio for detection of aldosterone-producing adenoma: the Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) study. J Am Heart Assoc. 2017;6:e005574. 3. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized preva lence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20. 4. Funder JW, Carey RM, Mantero F, et al. The management of primary aldo steronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889–1916. Downloaded from http://ahajournals.org by on October 7, 2026